Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 14/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28449516 | 0.87 | DRD2 (0.43) | RAD52RECQLGRM5NPC1RAB9A | |
| SCHEMBL5908794 | 0.86 | GRM5 (0.55) | RAD52RECQLGRM5NPC1RAB9A | |
| SCHEMBL765407 | 0.85 | RAD52 (0.41) | RAD52RECQLGRM5NPC1RAB9A | |
| SCHEMBL985377 | 0.82 | GRM5 (0.45) | GRM5NPC1RAB9A | |
| SCHEMBL10825454 | 0.82 | RAD52 (0.51) | RAD52RECQLGRM5NPC1RAB9A | |
| SCHEMBL15240212 | 0.82 | RAD52 (0.48) | RAD52RECQLGRM5NPC1RAB9A | |
| SCHEMBL17933982 | 0.82 | RAD52 (0.51) | RAD52RECQLGRM5NPC1RAB9A | |
| SCHEMBL22396285 | 0.81 | GRM5 (0.44) | GRM5NPC1RAB9A | |
| SCHEMBL28895700 | 0.81 | GRM5 (0.44) | GRM5NPC1RAB9A | |
| SCHEMBL28371109 | 0.80 | NPC1 (0.44) | RAD52RECQLGRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024088407-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州圣域生物医药科技有限公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-117946138-A | And ring nitrogen-containing compound, intermediate thereof, preparation method and application | 杭州圣域生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117903166-A | Novel ASK1 inhibitor and preparation method and application thereof | 中国药科大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-114728926-A | ROCK inhibitor and preparation method and application thereof | 武汉朗来科技发展有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113874074-A | HMOX1 inducers | 米托布里奇公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-111592534-A | Novel compounds | 特殊治疗有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-107001339-B | Novel compounds | 特殊治疗有限公司 | 2020-03-17 | — | — | CN | disclosed |
| EP-3484878-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1562958-A1 | N-SULFONYLAMINOTHIAZOLE | Novartis AG (CH) | 2005-08-17 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| WO-2004043968-A1 | N-SULFONYLAMINOTHIAZOLE | NOVARTIS AG (CH) | 2004-05-27 | — | — | WO | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | RAD52 1989/4885RECQL 250/4885GRM5 2706/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | RAD52 1613/4885RECQL 23/4885GRM5 2219/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | RAD52 1613/4885RECQL 23/4885GRM5 2219/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | RAD52 1613/4885RECQL 23/4885GRM5 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.